Pharmacokinetics (PK)

PROJECT SUMMARY/ABSTRACT (PHARMACOKINETICS SHARED RESOURCE) The Pharmacokinetics Shared Resource (PK-SR) was founded in 2009 and has been funded by the CCSG since 2012. PK-SR is led by Co-Directors Duxin Sun (DT) and Amit Pai (DT) with eleven full time staff members and eight LC-MS instruments. PK-SR plays a pivotal role in advancing the drug discovery, drug optimization, and clinical translation of novel anti-cancer therapeutics. PK-SR has a thirteen-year track record of supporting lead compound selection in cancer drug discovery/optimization based on in vitro and in vivo ADME (absorption, distribution, metabolism, and excretion) and preclinical pharmacokinetic (PK) platforms. The strong bioanalytical and PK knowledge of the SR also supports the clinical PK needs of investigators performing phase I/II clinical trials in patients. Rogel Cancer Center (Rogel) members benefit from the resources and strategic advice offered. PK-SR plays a pivotal role in guiding key experimental decisions to help streamline studies to maximize information gain at the lowest cost. This approach has contributed to major scientific advancements led by Rogel members. PK-SR operates based on an academic research organization framework to rapidly inform go or no- go decisions on key compounds under investigation by Rogel members. PK-SR also collaborates on joint grant and patent applications and helps generate high-impact publications.